Research programme: JAK3 inhibitors - Pfizer

Drug Profile

Research programme: JAK3 inhibitors - Pfizer

Alternative Names: PS 608504; WYA-152038/PS 513992

Latest Information Update: 05 Apr 2011

Price : $50

At a glance

  • Originator Pharmacopeia Drug Discovery
  • Developer Ligand Pharmaceuticals; Pfizer
  • Class
  • Mechanism of Action Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Eye disorders; Inflammation; Psoriasis

Highest Development Phases

  • Preclinical Immunological disorders; Inflammation

Most Recent Events

  • 05 Apr 2011 Ligand's JAK3 inhibitors (topical) are available for licensing. www.ligand.com
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 01 Sep 2009 Pharmacodynamics and pharmacokinetics data from a preclinical trial in inflammation/rheumatoid arthritis presented at the 238th National Meeting of the American Chemical Society (ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top